In Vivo Evaluation of a New Recombinant Hyaluronidase to Improve Gene Electro-Transfer Protocols for DNA-Based Drug Delivery against Cancer
Cancer vaccines based on plasmid DNA represent a good therapeutic perspective, despite their low potency. Animal-derived hyaluronidases (Hyals) are employed in oncological clinical practice. Hyal has been also demonstrated to be a good enhancer of intramuscular Gene Electro-Transfer (GET) efficiency...
Main Authors: | Mariangela De Robertis, Lise Pasquet, Luisa Loiacono, Elisabeth Bellard, Luciano Messina, Susanna Vaccaro, Roberta Di Pasquale, Vito Michele Fazio, Marie-Pierre Rols, Justin Teissie, Muriel Golzio, Emanuela Signori |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-10-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/10/11/405 |
Similar Items
-
Hyaluronidase pharmacological properties and clinical application in ophthalmology
by: V. E. Zabanova, et al.
Published: (2020-08-01) -
Study of the immunotoxic properties of pegylated hyaluronidase
by: K. I. Ershov, et al.
Published: (2023-10-01) -
Hyaluronidases in Human Diseases
by: Aditya Kaul, et al.
Published: (2021-03-01) -
Hyaluronidase: An overview of its properties, applications, and side effects
by: Hyunwook Jung
Published: (2020-07-01) -
Characterization of Hyaluronidase 4 Involved in the Catabolism of Chondroitin Sulfate
by: Shuhei Yamada, et al.
Published: (2022-09-01)